Navigation Links
NeoVista, Inc. Announces the Launch of VIDION ANV Therapy System in UK for Treating Wet Age-Related Macular Degeneration
Date:11/16/2009

King’s College Hospital, London, Performs First Pioneering Surgical Procedure.

Fremont, CA and London, UK (PRWEB) November 16, 2009 -- NeoVista, Inc. announced today that the company’s revolutionary new surgical device is now available in the UK and offers fresh hope to 250,000 patients with wet age-related macular degeneration (AMD) –- a debilitating and aggressive eye condition that can lead to blindness within 3 months if left untreated. Every year 26,000 new cases of wet AMD are diagnosed in the UK.

The VIDION® Anti NeoVascular (ANV®) Therapy System, developed by NeoVista Inc and distributed by Carleton Ltd in the UK, has recently received a CE mark certifying that it has met the EU’s Medical Device Directive.

The new device is initially being introduced in 15 hospitals across the UK as part of a large clinical trial called MERLOT, where it will be used in patients whose current standard of care treatment involves regular injections of a drug into the eye to control their condition (up to one injection every month, indefinitely). Although the treatment is initially only available at select hospitals, it is anticipated that the number of sites using the device will increase quickly, to provide nationwide availability.

The MERLOT trial has been recently awarded portfolio status by The National Institute for Health Research (NIHR) Comprehensive Clinical Research Network (CCRN). The CCRN was created as part of the government’s research and development strategy, “Best Research for Best Health” to provide a world-class infrastructure for clinical trials in all areas of disease and clinical need within the NHS in UK.

Mr Tim Jackson, a Consultant Eye Surgeon at King’s College Hospital, who is the lead investigator for MERLOT said: “This is a relatively straightforward operation and the published results are
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization
2. NeoVista, Inc. Announces Initial VIDION Shipments
3. Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine
4. Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes'
5. Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine
6. Concuity Announces Next-Generation Revenue Cycle Management Solution
7. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
8. Westaim announces 2009 third quarter results
9. Human Pheromone Sciences Announces Third Quarter Results
10. Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party
11. Echo Therapeutics Announces $3 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... associated with a small increased risk of prostate cancer, ... cancer according to a new study from Harvard School ... association remained even among men who received regular PSA ... be explained by diagnostic bias. It is the largest ... the link between vasectomy and prostate cancer. , The ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... conditions are likely to change their preferences for receiving ... to new findings. The study, which will ... in Amsterdam today (26 September 2011), suggests that different ... but this will often go unnoticed by their healthcare ...
... new study has shown that people with chronic obstructive ... are at a serious risk of developing cardiovascular disease. ... September 2011) at the European Respiratory Society,s Annual Congress ... lung function should be routinely screened for cardiovascular disease, ...
... a phase III clinical trial have shown that ... women with advanced breast cancer resistant to hormonal ... European Multidisciplinary Cancer Congress [1] that women treated ... an improved progression-free survival of nearly seven months ...
... Reporter , FRIDAY, Sept. 23 (HealthDay News) -- Many studies ... a day is heart-healthy, and much of the benefit has ... red wine called polyphenols. But a new Dutch study ... not lower blood pressure after all. Study author ...
... trial comparing tamoxifen with the aromatase inhibitor letrozole ... of time and continues to prevent breast cancer ... post-menopausal women with hormone receptor-positive early breast cancer. ... 2011 European Multidisciplinary Cancer Congress [1], in Stockholm ...
... The Netherlands: Belly fat, known clinically as central obesity, has ... study. The findings, which will be presented at the ... 2011), have shown central obesity as a risk factor for ... a number of health effects, such as diabetes and heart ...
Cached Medicine News:Health News:Study shows decisions over life-sustaining treatment are likely to change 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy 2Health News:Antioxidants Not Behind Red Wine's Healthy Effect on Heart: Study 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4Health News:'Belly fat' linked to development of asthma 2
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Inc. (Nasdaq: OPTR ) announced today the ... 3 trials in patients with Clostridium difficile ... Infectious Disease Society of America (IDSA) in Vancouver, British ... M.D., of the University of Oxford, presented combined data ...
... PARK, Kan., Oct. 22 Mid*Lands IRB, LLC is ... by the Association for the Accreditation of Human Research ... Council on Accreditation.   Located in the ... board (IRB) that protects the rights and welfare of ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants 2
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 100 mg/dL (35.6 ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
Medicine Products: